# Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma

> **NCT01496807** · PHASE1 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 31 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Sylatron
- **DRUG:** Yervoy

## Key facts

- **NCT ID:** NCT01496807
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-17
- **Primary completion:** 2016-03-16
- **Final completion:** 2016-08-29
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2017-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01496807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01496807, "Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01496807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*